MedTrace Logo

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

NCT00228176 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 661

Last updated 2016-05-20

No results posted yet for this study

Summary

Objectives:

* Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT)
* Secondary: To evaluate the safety and tolerability of the above rimonabant regimen in the study population of atherosclerosis patients.

Conditions

  • Carotid Artery Plaque
  • Arteriosclerosis
  • Obesity
  • Metabolic Syndrome X

Interventions

DRUG

Rimonabant

Tablet, oral administration

DRUG

Placebo (for Rimonabant)

Tablet, oral administration

Sponsors & Collaborators

Principal Investigators

  • John JP Kastelein, MD · Amsterdam UMC, location VUmc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United States
  • Canada
  • France
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00228176 on ClinicalTrials.gov